Back to search results

Weight Loss and Pelvic Floor Symptoms Study

This study is looking at how different weight loss treatments affect pelvic floor symptoms in women. Pelvic floor symptoms include issues like leaking urine (urinary incontinence), needing to go to the bathroom often (urinary urgency), or a feeling of something falling out of the vagina (pelvic organ prolapse). Researchers want to compare women who are having weight loss surgery (like gastric sleeve or gastric bypass) with women who are taking a GLP-1 receptor agonist for weight loss. The study will measure changes in your pelvic floor symptoms using surveys after 6 months. You can join if you are a woman between 18 and 89 years old, have a BMI of 30 or higher, and are already a patient at Obesity Medicine and Metabolic & Bariatric Surgery for weight loss.

Study design
This is an observational study with a planned enrollment of 200 women. It compares two groups of patients receiving different weight loss treatments.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your pelvic floor symptoms will be measured at 6 months after starting your weight loss treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07175805

Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy

Not Yet Recruiting
Not specifiedAges 18–90Observational
Hartford HealthCare
~200 participants
Updated 2025-09-16 on ClinicalTrials.gov
What's tested:Bariatric SurgeryGLP1 receptor agonist

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in pelvic floor symptoms measured by survey the Urogenital Distress Inventory (UDI)
Measured over 6 months
+1 more outcome measured

Conditions

Lower Urinary Tract Symptoms
Stress Urinary Incontinence
Urge Urinary Incontinence
Overactive Bladder
Pelvic Organ Prolapse
Weight Loss
Fecal Incontinence
Bariatric Surgery
glp1 Agonist

Explore related trials

Fecal IncontinenceGenuine stress incontinenceLower Urinary Tract SymptomsOveractive BladderPelvic Organ ProlapseUrge incontinence of urine

Where it's being run

1 sites across 1 states
Connecticut1

Who to contact

Madeline Carmain, MD
[email protected]
860.972.4338
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

female
18-89 years old
any race/ethnicity
BMI ≥30 kg/m2
current medical weight loss or surgical weight loss patient of Obesity Medicine and Metabolic \& Bariatric Surgery
able/willing to give informed consent
have a home scale to measure weight
prescribed and start a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a GLP-1/gastric inhibitory peptide (GIP1)
taking other weight loss agents (such as metformin)
plan to undergo gastric sleeve or gastric bypass surgery
taking weight loss agents which are not GLP-1 RA or GLP-1/GIP1 medications at the start of the study. Patients will not be excluded if they are started on GLP-1 RA or GLP-1/GIP1 medications after surgery.

Exclusion

Pregnant
≥90 years old
\<18 years old
BMI \<30 kg/m2
A history of bariatric surgery prior to enrollment
No home scale to measure weight
Active cancer

What this trial measures

  • Change in pelvic floor symptoms measured by survey the Urogenital Distress Inventory (UDI)6 months

    The investigators plan to measure the change in pelvic floor symptoms between woman taking glucagon-like peptide-1 receptor agonists (GLP1) medications vs women receiving bariatric surgery. These changes will be measured by validated survey, including the Urogenital Distress Inventory (UDI)

  • Change in pelvic floor symptoms measured by validated survey the Colorectal-Anal Distress Inventory (CRADI-8).6 months

    The investigators plan to measure the change in pelvic floor symptoms between woman taking glucagon-like peptide-1 receptor agonists (GLP1) medications vs women receiving bariatric surgery. These changes will be measured by validated survey the Colorectal-Anal Distress Inventory (CRADI-8).